ReviewEuropean journal of medical research2025
Advances in multi-omics studies of microvascular invasion in hepatocellular carcinoma.
Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CECT Radiomics and Liver Fibrosis Markers for Predicting Early Recurrence in Older Patients with Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Explainable artificial intelligence and ensemble learning for hepatocellular carcinoma classification: State of the art, performance, and clinical implications.World journal of hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Microvascular invasion (MVI) represents a pivotal independent prognostic factor for the recurrence of hepatocellular carcinoma (HCC) after surgery. It contributes to early intervention for potentially recurrent HCC to enhance patient outcomes and increase survival rates. Traditionally, the diagnosis of MVI has relied on postoperative pathological analysis, and accurate preoperative detection methodologies are lacking. Recent research suggests that multi-omics strategies play a role in definitively diagnosing MVI before surgery and offering personalized selection for clinical decision-making in HCC management. This review meticulously examines a multi-omics approach for the preoperative prediction of MVI in HCC patients, aiming to innovate diagnostic paradigms to anticipate postsurgical recurrence, thereby facilitating earlier and more personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.